



ЕВРОПЕЙСКИ ПАРЛАМЕНТ PARLAMENTO EUROPEO EVROPSKÝ PARLAMENT EUROPA-PARLAMENTET
EUROPÄISCHES PARLAMENT EUROOPA PARLAMENT ΕΥΡΩΠΑΪΚΟ ΚΟΙΝΟΒΟΥΛΙΟ EUROPEAN PARLIAMENT
PARLEMENT EUROPÉEN PARLAIMINT NA HEORPA PARLAMENTO EUROPEO EIROPAS PARLAMENTS
EUROPOS PARLAMENTAS EURÓPAI PARLAMENT IL-PARLAMENT EWROPEW EUROPEES PARLEMENT
PARLAMENT EUROPEJSKI PARLAMENTO EUROPEU PARLAMENTUL EUROPEAN
EURÓPSKY PARLAMENT EVROPSKI PARLAMENT EUROOPAN PARLAMENTTI EUROPAPARLAMENTET

**Organised by the Policy Department A-Economy & Science
for the Committee on the Environment, Public Health and
Food Safety (ENVI)**

Workshop on
"Advanced Therapy Medicinal Products"
Wednesday, 20 February 2013 from 13.00 to 14.45
European Parliament, Room A3E-2, Brussels

AGENDA

13.00 - 13.05

**Welcome and opening by Co-chairs of the Health Working Group,
Glenis WILLMOTT and Alojz PETERLE, MEPs**

13.05 - 13.10

**The current position of the European Commission. Incentives for
advanced therapy medicinal product development in Europe**

Ms. Sabine JUELICHER, head of unit Medicinal Products- authorisations,
EMA. DG SANCO, EC.

Part 1

Advanced Therapy Treatment: The Future for Healthcare

13.10 - 13.20

Cell therapy challenges

Prof. Stefaan VAN GOOL, head of the Laboratory of Pediatric Immunology,
University of Louvain (BE).

13.20 - 13.30

Gene therapy challenges

Dr. Jacques MALLET, Director of "Recherche Emérite" CNRS, Institute for
Brain and Spinal Cord (ICM), Paris; Adjunct Professor at the University of
California at San Francisco (UCSF); Member of the French Academy of
Sciences; (FR, US).

13.30 - 13.40

The voice of patients

Dr. Monica ENSINI, Scientific Director, EURORDIS (European Organisation for Rare Diseases).

13.40 - 13.55

Question Time

With the participation of Dr. Christian K. SCHNEIDER (chair) and Dr. Patrick CELIS (scientific administrator), Committee for Advanced Therapies (CAT), European Medicine Agency (EMA, EU).

Part 2

Technology Transfer: Bringing Healthcare Research to the Market

13.55 - 14.05

The costs for making advanced therapies available to patients

Dr. Panos KANAVOS, Reader in International Health Policy in the Department of Social Policy, London School of Economics (LSE) and Programme Director of the Medical Technology Research Group (MTRG) at LSE Health; (UK).

14.05 - 14.15

The role of small and medium-sized enterprises (SMEs)

Dr. Maria Luisa NOLLI, founder and Chief Executive Officer of Areta International, member of the Management Committee of Assobiotec, the Italian biotechnology industry association; (IT).

14.15 - 14.40

Question Time

With the participation of Dr. Christian K. SCHNEIDER (chair) and Dr. Patrick CELIS (scientific administrator), Committee for Advanced Therapies (CAT), European Medicine Agency (EMA, EU).

14.40 - 14.45

Conclusions

14.45 Closing